Applied Clinical Trials
A comprehensive listing of US departments and offices that includes the telephone numbers of directors, commissioners, and advisors.
Office for Human Research Protection
Director
Jerry Menikoff (240) 453-6900
Deputy Director and Director, Office of International Activities
Melody Lin (240) 453-8126
Associate Director, Regulatory Affairs
Michael Carome (240) 453-8237
Senior Advisor to the Director
Ivor Pritchard (240) 453-8230
Director, Division of Compliance Oversight
Kristina Borror (240) 453-8132
Director, Division of Education and Development
Elyse Summers* (240) 453-8236
Director, Division of Policy and Assurances
Irene Stith-Coleman (240) 453-8138
Office of the FDA Commissioner
Commissioner
Margaret Hamburg (301) 796-5000
Principal Deputy Commissioner
Joshua Sharfstein (301) 796-5040
Chief Counsel
Ralph Tyler (301) 796-8535
Deputy Commissioner for Policy, Planning and Budget
David Dorsey (301) 796-4800
Deputy Commissioner for Science & Public Health & Chief Scientist
Jesse Goodman (301)796-4880
Assistant Commissioner for Counterterrorism & Emerging Threats
Boris Lushniak (301) 796-8512
Director, Office of Critical Path Programs
Leonard Sacks* (301) 796-8490
Deputy Commissioner for International Programs
Murray Lumpkin (301) 796-8400
Associate Commissioner for International Programs
Mary Lou Valdez (301) 796-8400
Associate Commissioner for External Affairs
Beth Martino (301) 796-7603
Assistant Commissioner for External Relations
Larry Bachorik (301) 796-8643
Assistant Commissioner for Public Affairs
George Strait (301)796-4540
Director, Office of Special Health Issues
Theresa Toigo (301) 796-8460
Associate Commissioner for Special Medical Programs
Jill Warner* (301) 796-4810
Director, Office of Pediatric Therapeutics
Dianne Murphy (301) 796-8651
Director, Office of Combination Products
Thinh Nguyen (301) 796-8931
Director, Office of Orphan Products Development
Timothy Cote (301) 796-8662
Director, Office of Good Clinical Practice
Joanne Less (301) 796-8340
Senior Bioethicist
Sara Goldkind (301) 796-8340
Senior Advisor for Clinical Science
David Lepay (858) 550-3850
Senior Health Policy Analyst
Kathleen Pfaender (301) 796-8340
Senior Health Policy Analyst
Doreen Kezer (301) 796-8340
Policy Analyst
Marsha Melvin (301) 796-8340
Policy Analyst
Bridget Folz (301) 796-8340
Biophysicist
Jean Toth-Allen (301) 796-8340
Director, Office for Women's Health
Marsha Henderson (301) 796-9439
Director, National Center for Toxicological Research
William Slikker (870) 543-7203
Director, Center for Tobacco Products
Lawrence Deyton (877) 287-1373
Office of Regulatory Affairs
Associate Commissioner for Regulatory Affairs
Dara Corrigan (301) 796-8800
Assistant Commissioner for Field Operations
Michael Chappell (301) 827-3107
Assistant Commissioner for Compliance Policy
Steven Solomon (301) 827-3101
Center for Devices and Radiological Health
Director
Jeffrey Shuren (301) 796-5900
Deputy Director & Chief Scientist
William Maisel (301) 796-5900
Senior Associate Director
Lillian Gill (240) 796-5900
Director, Office of Device Evaluation
Christy Foreman* (301) 796-5550
Director, Office of Compliance
Steven Silverman (301) 796-5500
Director, Division of Bioresearch Monitoring
Michael Marcarelli (301) 796-5490
Director, Office of In Vitro Diagnostic Device Evaluation and Safety
Alberto Gutierrez (301) 796-5453
Director, Office of Surveillance and Biometrics
Susan Gardner (240) 796-5996
Center for Drug Evaluation and Research (CDER)
Director
Janet Woodcock (301) 796-5400
Deputy Director for Regulatory Programs
Douglas Throckmorton (301) 796-5400
Deputy Director for Clinical Science
Robert Temple (301) 796-2270
Associate Director for International Programs
Justina Molzon (301) 796-5400
Associate Director for Regulatory Policy
Jane Axelrad (301) 796-5400
Associate Director for Planning and Business Informatics
Theresa Mullin (301) 796-3422
Director, Office of Executive Programs
Deborah Henderson (301) 796-1446
Director, Office of Management
Marg Milline (301) 796-3300
Director, Office of Communication
Julie Zawisza (301) 796-3700
Director, Office of Counterterrorism and Emergency Coordination
Rosemary Roberts (301) 796-2210
Office of Translational Services
Director
ShaAvhree Buckman (301) 796-1721
Director, Office of Clinical Pharmacology
Lawrence Lesko (301) 796-1565
Director, Office of Biostatistics
Robert O'Neill (301) 796-1700
Office of Compliance
Director
Deborah Autor (301) 796-3100
Deputy Director
Ilisa Bernstein* (301) 796-3100
Director, Division of Scientific Investigations
Leslie Ball (301) 796-3150
Deputy Director
Joseph Salewski (301) 796-3395
Chief, Good Clinical Practices Branch I
Constance Lewin (301) 796-3397
Chief, Good Clinical Practices Branch II
Tejashri Purohit-Sheth (301) 796-3402
Chief, GLP/Bioequivalence Branch
Sam Haidosh (301) 796-4477
Office of Medical Policy
Director
Rachel Behrman (301) 796-2500
Director, Division of Drug Marketing, Advertising, and Communications
Thomas Abrams (301) 796-1200
Director, Office of Planning & Informatics
Theresa Mullins (301) 796-3422
Office of New Drugs
Director
John Jenkins (301) 796-0700
Deputy Director
Sandra Kweder (301) 796-0700
Director, Office of Drug Evaluation I
Robert Temple* (301) 796-2270
Director, Office of Drug Evaluation II
Curtis Rosebraugh (301) 796-2310
Director, Office of Drug Evaluation III
Julie Beitz (301) 796-2100
Director, Office of Antimicrobial Products
Edward M. Cox (301) 796-1300
Director, Office of Oncology Products
Richard Pazdur (301) 796-2340
Director, Office of Nonprescription Products
Charles Ganley (301) 796-0895
Office of Pharmaceutical Science
Director
Helen Winkle (301) 796-2400
Director, Science & Research Staff
Nakissa Sadrieh (301) 796-1598
Director, Office of New Drug Quality Assessment
Moheb Nasr (301) 796-1724
Director, Office of Generic Drugs
Keith Webber* (240) 276-9310
Director, Office of Testing and Research
Vincent Vilker (301) 796-0200
Director, Office of Biotechnology Products
Steven Kozlowski (301) 796-2390
Office of Surveillance and Epidemiology
Director
Gerald DalPan (301) 796-2380
Deputy Director
Henry "Skip" Francis (301) 796-2380
Director, Division of Risk Management
Mary Willy (301) 796-5400
Director, Division of Epidemiology
Solomon Iyasu (301) 796-2370
Director, Division of Medication Error Prevention and Analysis
Carol Holquist (301) 796-2360
Director, Division of Pharmacovigilance I
Mark Avigan (301) 796-2350
Director, Division of Pharmacovigilance II
Robert Boucher (301) 796-2350
Center for Biologics Evaluation and Research (CBER)
Director
Karen Midthun (301) 827-0372
Senior Scientist for Emerging & Pandemic Threat Preparedness
David Cho (301) 827-6352
Associate Director for Research
Carolyn Wilson (301) 827-0481
Associate Director for Policy
Diane Maloney (301) 827-0372
Associate Director for Quality Assurance
Sheryl Lard-Whiteford (301) 827-0379
Associate Director for Review Management
Robert Yetter (301) 827-0373
Science Communications Advisor
Marc Kusinitz (301) 827-0372
Senior Advisor for International Affairs
Joan W. Blair (301) 827-0639
Senior Advisory for Counterterrorism/Medical Countermeasures:
Cynthia Kelley (3010 827-0636
Senior Advisor for Chemistry and Manufacturing Controls
Christopher Joneckis (301) 435-5681
Director, Office of Biostatistics and Epidemiology
Robert Ball (301) 827-3034
Director, Office of Information Technology
Ginger Leo (301) 827-1368
Director, Office of Communication,Outreach & Development
Lorrie McNeill (301) 827-2000
Director, Office of Management
James Sigg (301) 827-1320
Director, Office of Information Technology
Ginger Leo (301) 827-1368
Director, Office of Blood Research & Review
Jay Epstein (301) 827-3518
Director, Office of Vaccines Research & Review
Norman Baylor (301) 827-5105
Director, Office of Cellular, Tissue, and Gene Therapies
Celia Witten (301) 827-5102
Director, Office of Compliance & Biologics Quality
Mary Anne Malarkey (301) 827-6190
Director, Division of Inspections & Surveillance
Gilliam Conley (301) 827-6220
Director, Bioresearch Monitoring Branch
Patricia Holobaugh (301) 827-6220
NIH Institutes, Center, and Divisions
*Acting
**E-mail for FDA staff:firstname.lastname@fda.hhs.gov
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Citius Pharmaceuticals Resubmits BLA to FDA for Lymphir to Treat Cutaneous T-Cell Lymphoma
March 19th 2024Pivotal Phase III Study 302 trial data show an objective response rate of 36.2% based on an independent review committee assessment in the treatment of relapsed/refractory cutaneous T-cell lymphoma.